The World Health Organization (WHO) today recommended, for the first time, the new generation of successful therapies against obesity and diabetes, while demanding cheaper generic versions for developing countries.
The who added semaglutide – the active ingredient of the Ozempic and Wegovy of the Danish pharmaceutical industry Novo Nordisk -, Doulaglutidis and Liglutidis, as well as Tirzepatide – used in the Mounjaro formulation of Eli Lilly – to the Eli Lilly Mounjaro formulation.
Need for more and cheaper generic
Based on the body’s data, more than 3.7 million people died in 2021 from diseases associated with obesity – more than those who died of basic, deadly infectious diseases, malaria, tuberculosis and AIDS together.
New treatments for diabetes and obesity enhance the action of a hormone that affects the secretion of insulin (GLP-1) and in general the feeling of satiety.
Initially these formulations were developed for diabetes, but have shown remarkable results in weight loss and are considered by experts a significant therapeutic progress, despite restrictions.
However, their high price, which may exceed for example $ 1,000 monthly In the US, it “restricts access to these formulations”, observed, expressing concern that low -income countries would be deprived of them.
In order to ensure that these “saving” injectable treatments will reach those who need them most, the who has called for “to encourage competition through generic drugs to reduce prices”.
According to Andrew Hill, a pharmacology researcher at the University of Liverpool, studies show that Generic Semaglutide could be massively produced in India at just $ 4 a month.
Semaglutidis’s patent will end in 2026 in some countries, including Canada, India and China, which could also encourage the production of generic drugs.
In addition to diabetes and obesity, these preparations appear to be linked to the improvement of various pathologies.
According to a report published this week in the journal Jama, the risk of hospitalization or premature death decreases by 40% in patients with heart problems and taking these medicines.
More than a billion people worldwide were affected by obesity and more than 800 million in 2022, according to WHO.
Source :Skai
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
